RxDoctor Payments Data

Paul Corona, MD

Family Medicine · Laguna Niguel, CANPI 1194876219

Payments from drug & device makers

$21,773in general payments, 2019–2025

Across 774 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biocomposites Inc$7K
  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • Tris Pharma Inc$751
  • plus $6K from 28 others

What the payments were for

  • Consulting fees$6,50530%
  • Food & beverage$15,21970%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,773 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$33,906
Medicare patients
143
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole36$50,983
VraylarCariprazine Hcl21$23,417
Effexor XrVenlafaxine Hcl15$19,383
Desvenlafaxine Succinate ErDesvenlafaxine Succinate206$13,144
Bupropion XlBupropion Hcl488$10,993
Quetiapine Fumarate295$6,221
Aripiprazole141$5,808
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine77$5,736
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine156$4,782
VyvanseLisdexamfetamine Dimesylate12$4,750
Lisdexamfetamine Dimesylate15$3,667
Venlafaxine Hcl ErVenlafaxine Hcl219$3,564
Gabapentin153$2,669
Olanzapine73$2,269
Topiramate193$2,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$2,175$50,98336 claims
AbbVieVraylar$3,295$23,41721 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$542$4,75012 claims
Lilly USA, LLCOlanzapine$19$2,26973 claims
Upsher-smith Laboratories LLCTopiramate$144$2,061193 claims
Almatica Pharma LLCSertraline Hcl$698$15851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Laguna Niguel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →